Out to pi­o­neer gene edit­ing in Chi­na, Edi­Gene bags $67M to be­gin clin­i­cal test­ing for β-tha­lassemia ther­a­py, uni­ver­sal CAR-T

A gene edit­ing play­er hail­ing from Bei­jing has clinched $67 mil­lion to steer two of its lead can­di­dates in­to the clin­ic — and to prove it­self as a CRISPR pi­o­neer in Chi­na.

Edi­Gene gath­ered the Se­ries B from a slate of top-tier Chi­nese in­vestors, in­clud­ing 3H Health In­vest­ment (who led the round), Se­quoia Cap­i­tal Chi­na, Al­win Cap­i­tal and Kun­lun Cap­i­tal. Pre­vi­ous back­ers, in­clud­ing IDG Cap­i­tal, Lil­ly Asia Ven­ture, Hua­gai Cap­i­tal and Green Pine Cap­i­tal Part­ners, al­so par­tic­i­pat­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER